Revive Therapeutics Signs MOU with Attwill Medical Solutions for Phase 3 Clinical Trial for Bucillamine in COVID-19 Post published:August 14, 2020 Post category:Press Release
Mind Medicine (MindMed) Inc. Announces Q2 2020 Financial Results Post published:August 14, 2020 Post category:Press Release
Mota Ventures to Change Name to Thoughtful Brands Inc. (CSE: TBI) Post published:August 13, 2020 Post category:Press Release
Tryp Therapeutics Partners with Albany Molecular Research Inc. to Manufacture a Proprietary Psilocybin-based Drug Post published:August 13, 2020 Post category:Press Release
Mydecine Innovations Group Featured in Forbes for the First-Of-Its-Kind Clinicals Using Psilocybin Therapy For PTSD Post published:August 13, 2020 Post category:Press Release
MindMed Expanding R&D in Europe, Appoints Dr. Miri Halperin Wernli As President Post published:August 13, 2020 Post category:Press Release
Field Trip Psychedelics Inc. Expands Stateside With Psychedelic-Enhanced Psychotherapy Clinic in New York City Post published:August 13, 2020 Post category:Press Release
Yield Growth Announces Name Change and Provides Corporate Update Post published:August 13, 2020 Post category:Press Release
Mydecine Innovations Group Provides Inaugural Corporate Update in the Expanding Psychedelic Medicines Sector Post published:August 12, 2020 Post category:Press Release
Revive Therapeutics Advancing Drug Delivery Technology for Psychedelics Post published:August 11, 2020 Post category:Press Release